BIOLASE Technology Inc., the world’s leading dental laser manufacturer and distributor, today announced that the U.S. Patent and Trademark Office has issued the company a new patent for the use of its laser technologies for treating farsightedness (presbyopia and hyperopia).

The patent, entitled, “Methods for Treating Hyperopia and Presbyopia via Laser Tunneling,” covers the use of Erbium-based pulsed lasers designed to mitigate the effects of presbyopia, which in turn enables the eye to refocus at near distance without losing its ability to focus at a distance.

Federico Pignatelli, BIOLASE chairman and CEO, said the patent correlates with the company’s current technology applications and said it positions the company as an ideal partner for ophthalmic companies looking for innovation.

“Our laser technologies have broad applications within dentistry and other medical fields such as ophthalmology. This strong patent position in combination with our already FDA-cleared general indications for using our lasers with ocular tissue and the tissue surrounding the eye and orbit makes us an attractive partner for an ophthalmic company who needs the IP, innovative technology and expertise necessary to enter the biggest potential market in ophthalmology,” Pignatelli stated in the press release. “Presbyopia is a perfect fit for our patented Er,Cr:YSGG Waterlase technology and the first of several other major medical applications in dermatology, cosmetic surgery, orthopedics, urology and ENT that we plan to commercialize or license in the near future.”

This new patent is BIOLASE’s first U.S. patent within its Ophthalmic Patent Family IV, and is one of a total of seven issued and 20 pending U.S. and International patents in the four families in the field of ophthalmology.

Pignatelli also noted the differences of BIOLASE technology compared to currently used approaches to treat farsightedness. The technology restores normal accommodative functioning to improve immediate distance vision, unlike approaches that involve the altering of the cornea or lens. It is also without glare, depth perception, or intermediate vision.

“The unique laser-tissue interaction of the YSGG laser, which is the heart of Waterlase technology, combines the very best characteristics of the Er:YAG and short pulse CO2s that are currently the standard for many medical laser procedures. Our new 2R technology, utilized in the recently introduced Waterlase® iPlus™ which is faster, more powerful, more versatile and easier to operate, creates significant differentiation and advantages for non-dental clinical applications,” Chief Technology Officer Dmitri Boutoussov, PhD, concluded.

For more information visit www.biolase.com